Experimental cancer drug trial halted early

NCT ID NCT04799054

Terminated Disease control Sponsor: Ascendis Pharma Oncology Division A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effects. However, the trial was terminated before completion, so its full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TransCon TLR7/8 agonist (an investigational drug that activates the immune system) and pembrolizumab (an immunotherapy drug)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.

What could go wrong

This trial was terminated early, so results are limited. It was an early-phase study focused on safety and dosing, not yet on effectiveness. The drug may cause side effects or fail to shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma melanoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HPV ASSOCIATED CANCERS LOCALLY ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NEOADJUVANT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) NEOADJUVANT MELANOMA

Contacts and locations

Show contact details

Locations

Ascendis Investigational Site

Los Angeles, California, 90067, United States
Ascendis Investigational Site

Orange, California, 92868, United States
Ascendis Investigational Site

Tampa, Florida, 33612, United States
Ascendis Investigational Site

Dallas, Texas, 75235, United States
Ascendis Investigational Site

Dallas, Texas, 75390, United States
Ascendis Investigational Site

Houston, Texas, 77030, United States
Ascendis Investigational Site

Bedford Park, 5042, Australia
Ascendis Investigational Site

Amsterdam, 1066, Netherlands
Ascendis Investigational Site

Rotterdam, 3015 GD, Netherlands
Ascendis Investigational Site

Dalseo-gu, 42601, South Korea
Ascendis Investigational Site

Seocho-gu, 06591, South Korea
Ascendis Investigational Site

Seogu, 49201, South Korea
Ascendis Investigational Site

Seogu, 49267, South Korea
Ascendis Investigational Site

Seongnam, 13620, South Korea
Ascendis Investigational Site

Seoul, 03722, South Korea
Ascendis Investigational Site

Seoul, 05505, South Korea
Ascendis Investigational Site

Seoul, 06273, South Korea
Ascendis Investigational Site

Suwon, 16247, South Korea
Ascendis Investigational Site

Suwon, 16499, South Korea
Ascendis Investigational Site

Barcelona, 08003, Spain
Ascendis Investigational Site

Barcelona, 08028, Spain
Ascendis Investigational Site

Barcelona, 08035, Spain
Ascendis Investigational Site

Barcelona, 08908, Spain
Ascendis Investigational Site

Madrid, 28027, Spain
Ascendis Investigational Site

Madrid, 28040, Spain
Ascendis Investigational Site

Madrid, 28041, Spain
Ascendis Investigational Site

Madrid, 28050, Spain
Ascendis Investigational Site

Málaga, 29010, Spain
Ascendis Investigational Site

Murcia, 30120, Spain
Ascendis Investigational Site

Pamplona, 31008, Spain
Ascendis Investigational Site

Seville, 41009, Spain
Ascendis Investigational Site

Valencia, 46009, Spain
Ascendis Investigational Site

Taichung, 404, Taiwan
Ascendis Investigational Site

Taichung, 40705, Taiwan
Ascendis Investigational Site

Tainan, 704, Taiwan
Ascendis Investigational Site

Taipei, 112, Taiwan
Ascendis Pharma Investigational Site

Duarte, California, 91010, United States
Ascendis Pharma Investigational Site

San Francisco, California, 94158, United States
Ascendis Pharma Investigational Site

Chicago, Illinois, 60637, United States
Ascendis Pharma Investigational Site

Iowa City, Iowa, 52242, United States
Ascendis Pharma Investigational Site

Louisville, Kentucky, 40202, United States
Ascendis Pharma Investigational Site

Canton, Ohio, 44718, United States
Ascendis Pharma Investigational Site

Cincinnati, Ohio, 45219, United States
Ascendis Pharma Investigational Site

Cleveland, Ohio, 44106, United States
Ascendis Pharma Investigational Site

Pittsburgh, Pennsylvania, 15232, United States
Ascendis Pharma Investigational Site

Knoxville, Tennessee, 37920, United States
Ascendis Pharma Investigational Site

Fairfax, Virginia, 22031, United States
Ascendis Pharma Investigational Site

Wollongong, New South Wales, 2500, Australia
Ascendis Pharma Investigational Site

Frankston, Victoria, 3199, Australia